{"brief_title": "Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma", "brief_summary": "The purpose of the study is to determine whether seocalcitol is effective in the treatment of advanced primary liver cancer (hepatocellular carcinoma [HCC]).", "condition": "Liver Neoplasms", "intervention_type": "Drug", "intervention_name": "Seocalcitol", "criteria": "Inclusion Criteria: - Hospital in- or out-patients - Either sex - Aged 18-75 years - With hepatocellular carcinoma, verified by histology/cytology, which is not amenable to curative treatment or transplantation. - Patients must have measurable disease, and be classifiable as to Barcelona Clinic Liver Cancer (BCLC) stage 0, as described in Llovet JM et al. Hepatology 1999;29:62-67. Exclusion Criteria: - Patients treated with chemotherapy or other anti-cancer therapy within 4 weeks before visit 1 - Patients with another primary tumor, except for basocellular carcinoma of the skin or in situ carcinoma of the cervix, within the last 2 years - A history of renal stone(s) - A life expectancy of < 3 months - World Health Organization (WHO) performance status 3 or 4 - Okuda stage III. - Patients with hypercalcemia, or other clinically important laboratory abnormalities - Patients with previous/current calcium metabolic disease, taking calcium-lowering therapy, or medication known to affect systemic calcium metabolism are also excluded. - All patients must give their signed informed consent to join the study.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "id": "NCT00051532.xml"}